PE/Dazzle 594 anti-mouse CD169 Siglec-1 Antibody anti-CD169 - 3D6.112,BioLegend,142423

Additional reported applications (for the relevant formats) include: immunohistochemical staining in frozen tissue sections1, and spatial biology (IBEX)4,5.

Host

Rat

Reactivity

Mouse

Application

FC -Quality tested

Platform ID

BAB995680219

BioLegend

Headquarters

8999 BioLegend Way San Diego, CA 92121 United States

Contact

Tel: 1-858-455-9588
Fax: +49 (4131) 7023913

Email:

Product Specifications
Scientific Background

Specifications

NamePE/Dazzle 594 anti-mouse CD169 Siglec-1 Antibody anti-CD169 - 3D6.112
Cat. No.142423
HostRat
RRIDAB_2750058 (BioLegend Cat. No. 142423)AB_2750059 (BioLegend Cat. No. 142424)
IsotypeRat IgG2a, κ
ReactivityMouse
ApplicationFC -Quality tested
ClonalityMonoclonal
Clone Number3D6.112
Concentration0.2 mg/ml
TargetCD169
ImmunogenPurified Native Sialoadhesin from spleen
PurityThe antibody was purified by affinity chromatography and conjugated with PE/Dazzle™ 594 under optimal conditions.
FormulationPhosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
StorageThe antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light.Do not freeze.
Regulatory StatusResearch Use Only

Scientific Background

CD169, also known as Siglec-1 and Sialoadhesin (Sn), is a type I lectin containing 17 immunoglobulin (Ig) domains (one variable domain and 16 constant domains). CD169 binds to sialic acids, which can be found on PSGL-1, CD43, CD206, and CD227. By its affinity to α2, 3-linked sialic acid, it is involved in macrophage binding to different cell types such as granulocytes, monocytes, NK, B, and T cells. CD169 was initially identified as a sialic acid-dependent sheep erythrocyte receptor (SER) on resident bone marrow cells of mice. It has been identified as highly expressed on resident bone marrow macrophages which plays an important role in retention of stem cells in mesenchymal stem cell niche. It is also found on some specific subsets of tissue macrophages in spleen, lymph nodes, bone marrow, liver, colon, lungs, and cancer cells. Evidence suggest that CD169-positive macrophages serve as lymph node-resident APCs to dominate early activation of tumor antigen-specific CD8+T cells and invariant NK cell.

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.